Therapeutic effects of phosphodiesterase 5 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) and combined post- and pre-capillary pulmonary hypertension (Cpc-PH).
Event: ESC Congress 2017
Topic: Chronic pulmonary hypertension
Session: Pulmonary hypertension: pathophysiology
Therapeutic potential of phosphodiesterase 5 inhibitors in patients with heart failure with preserved ejection fraction (HFpEF) and combined post- and pre-capillary pulmonary hypertension (Cpc-PH).
Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure
Topic: Pulmonary hypertension
Session: Moderated Poster session 6 - Therapy
